Citius Pharmaceuticals Inc (NASDAQ:CTXR)’s share price was up 11.1% on Tuesday . The company traded as high as $1.04 and last traded at $1.00, approximately 66,073 shares were traded during trading. A decline of 56% from the average daily volume of 149,961 shares. The stock had previously closed at $0.90.

A number of research analysts have recently weighed in on CTXR shares. Zacks Investment Research downgraded shares of Citius Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, September 9th. Dawson James started coverage on shares of Citius Pharmaceuticals in a research report on Friday, September 6th. They set a “buy” rating and a $7.00 target price for the company.

The stock’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.15. The stock has a market capitalization of $22.07 million, a P/E ratio of -0.85 and a beta of 0.68.

A hedge fund recently raised its stake in Citius Pharmaceuticals stock. Vanguard Group Inc. increased its holdings in Citius Pharmaceuticals Inc (NASDAQ:CTXR) by 308.3% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 453,156 shares of the company’s stock after buying an additional 342,180 shares during the period. Vanguard Group Inc. owned 2.05% of Citius Pharmaceuticals worth $444,000 as of its most recent SEC filing. 2.83% of the stock is owned by institutional investors and hedge funds.

About Citius Pharmaceuticals (NASDAQ:CTXR)

Citius Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. The company develops Mino-Lok, which is in Phase III clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

See Also: How do investors use RSI to grade stocks?

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.